News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
184,645 Results
Type
Article (12966)
Company Profile (23)
Press Release (171656)
Section
Business (61999)
Career Advice (276)
Deals (11964)
Drug Delivery (39)
Drug Development (21048)
Employer Resources (41)
FDA (2627)
Job Trends (3811)
News (95458)
Policy (6930)
Tag
2024 BioCapital Digital (1)
2024 Biotech Bay Standard (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2026 Pharm Country Premier (1)
Academia (995)
Allergies (18)
Alliances (15008)
ALS (32)
Alzheimer's disease (512)
Antibody-drug conjugate (ADC) (46)
Approvals (2646)
Artificial intelligence (87)
Autoimmune disease (6)
Automation (2)
Bankruptcy (157)
Best Places to Work (2748)
BIOSECURE Act (8)
Biosimilars (25)
Biotechnology (20)
Bladder cancer (21)
Brain cancer (12)
Breast cancer (72)
Cancer (625)
Cardiovascular disease (49)
Career advice (230)
Career pathing (7)
CAR-T (45)
Cell therapy (125)
Cervical cancer (5)
Clinical research (16948)
Collaboration (262)
Compensation (24)
Complete response letters (4)
COVID-19 (758)
CRISPR (13)
C-suite (93)
Cystic fibrosis (51)
Data (598)
Denatured (8)
Depression (11)
Diabetes (53)
Diagnostics (1615)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (9)
Drug discovery (39)
Drug pricing (37)
Drug shortages (2)
Duchenne muscular dystrophy (23)
Earnings (24053)
Editorial (14)
Employer branding (10)
Employer resources (33)
Events (18154)
Executive appointments (262)
FDA (2921)
Featured Employer (4)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (652)
Gene editing (35)
Generative AI (9)
Gene therapy (95)
GLP-1 (204)
Government (1228)
Guidances (19)
Healthcare (5219)
Huntington's disease (4)
IgA nephropathy (15)
Immunology and inflammation (40)
Indications (3)
Infectious disease (803)
Inflammatory bowel disease (37)
Inflation Reduction Act (6)
Influenza (20)
Intellectual property (33)
Interviews (37)
IPO (6478)
IRA (20)
Job creations (1126)
Job search strategy (219)
Kidney cancer (1)
Labor market (15)
Layoffs (179)
Leadership (2)
Legal (1577)
Liver cancer (23)
Lung cancer (71)
Lymphoma (40)
Machine learning (2)
Management (10)
Manufacturing (86)
MASH (28)
Medical device (3132)
Medtech (3134)
Mergers & acquisitions (5656)
Metabolic disorders (181)
Multiple sclerosis (21)
NASH (7)
Neurodegenerative disease (29)
Neuropsychiatric disorders (8)
Neuroscience (674)
NextGen: Class of 2025 (2196)
Non-profit (2416)
Northern California (779)
Now hiring (4)
Obesity (91)
Opinion (109)
Ovarian cancer (22)
Pain (24)
Pancreatic cancer (30)
Parkinson's disease (44)
Partnered (10)
Patents (63)
Patient recruitment (28)
Peanut (13)
People (18401)
Pharmaceutical (4)
Phase I (5701)
Phase II (8078)
Phase III (5085)
Pipeline (561)
Podcasts (26)
Policy (49)
Postmarket research (433)
Preclinical (2290)
Press Release (10)
Prostate cancer (33)
Psychedelics (7)
Radiopharmaceuticals (83)
Rare diseases (126)
Real estate (1360)
Recruiting (14)
Regulatory (4595)
Reports (12)
Research institute (924)
Resumes & cover letters (45)
RNA editing (1)
RSV (8)
Schizophrenia (25)
Series A (122)
Series B (80)
Service/supplier (2)
Sickle cell disease (15)
Southern California (729)
Special edition (8)
Spinal muscular atrophy (61)
Sponsored (5)
Startups (2985)
Stomach cancer (3)
Supply chain (11)
The Weekly (17)
United States (6488)
Vaccines (184)
Venture capitalists (37)
Webinars (7)
Weight loss (49)
Women's health (9)
Worklife (3)
Date
Today (89)
Last 7 days (254)
Last 30 days (1009)
Last 365 days (10920)
2025 (2714)
2024 (11305)
2023 (12405)
2022 (16752)
2021 (16993)
2020 (16499)
2019 (13712)
2018 (10671)
2017 (10021)
2016 (8588)
2015 (10244)
2014 (7149)
2013 (5312)
2012 (5603)
2011 (6095)
2010 (5743)
Location
Africa (221)
Alabama (13)
Alaska (3)
Arizona (43)
Arkansas (5)
Asia (10861)
Australia (1940)
California (1827)
Canada (813)
China (106)
Colorado (97)
Connecticut (91)
Delaware (34)
Europe (25712)
Florida (263)
Georgia (51)
Idaho (8)
Illinois (129)
India (7)
Indiana (59)
Iowa (1)
Japan (61)
Kansas (31)
Kentucky (6)
Louisiana (6)
Maine (15)
Maryland (229)
Massachusetts (1327)
Michigan (25)
Minnesota (84)
Missouri (19)
Montana (3)
Nebraska (2)
Nevada (18)
New Hampshire (17)
New Jersey (489)
New Mexico (8)
New York (573)
North Carolina (246)
Northern California (779)
Ohio (60)
Oklahoma (3)
Oregon (5)
Pennsylvania (344)
Puerto Rico (4)
Rhode Island (9)
South America (266)
South Carolina (5)
Southern California (729)
Tennessee (19)
Texas (234)
Utah (36)
Virginia (52)
Washington D.C. (29)
Washington State (175)
West Virginia (1)
Wisconsin (12)
184,645 Results for "novartis venture funds".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Venture capitalists
Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs
The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.
January 10, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Salience Labs Closed Series A Round Led by Applied Ventures and ICM HPQC Fund
February 7, 2025
·
4 min read
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
·
2 min read
·
Tristan Manalac
Business
Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis
Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.
August 22, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Venture Fund
January 10, 2025
·
3 min read
1 of 18,465
Next
